Pliant Therapeutics (PLRX) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future
2. 02We will require substantial additional capital to fund our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations
3. 03The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline

Risks Related to Research and Development and the Biopharmaceutical Industry

1. 04We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success
2. 05Our business is highly dependent on the success of our lead product candidate, bexotegrast and any other product candidates that we advance into the clinic. Our product candidates will require significant additional development before we may be able to seek regulatory approval for and launch a product commercially
3. 06Our approach to drug discovery and development in the area of fibrotic diseases, with an initial focus on tissue-specific integrin modulation and TGF-β signaling inhibition, is unproven and may not result in marketable products
4. 07Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome
5. 08We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of bexotegrast or any other product candidates
6. 09Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates
7. 10planned trials, and may be required to further test our candidates, including additional drug-drug interaction studies, which may be expensive, time-consuming and result in delays to our programs
8. 11If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
9. 12The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced
10. 13Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates
11. 14A Fast Track designation by the FDA, even if granted for other current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
12. 15Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
13. 16We may not be successful in our efforts to identify or discover additional product candidates in the future
14. 17Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business
15. 18If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates
16. 19We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than us
17. 20The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

1. 21Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 22Coverage and reimbursement may be limited or unavailable or pricing unfavorable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably
3. 23In the United States as well as foreign jurisdictions, no uniform policy of coverage and reimbursement for products exists among third-party payors
4. 24Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential
5. 25The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment. Ensuring business arrangements comply with applicable healthcare laws can be time- and resource-consuming
6. 26Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations
7. 27Drug marketing and reimbursement regulations may materially affect our ability to market and secure reimbursement for our products
8. 28to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment
9. 29Additional laws and regulations governing international operations could negatively impact or restrict our operations

Risks Related to Our Intellectual Property

1. 30Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
2. 31We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates
3. 32patents or other intellectual property rights or will design around the claims of patents that may issue that cover our products
4. 33We may enter into license or other collaboration agreements that may impose certain obligations on us. If we fail to comply with our obligations under such agreements with third parties, we could lose license rights that may be important to our future business
5. 34If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
6. 35information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed
7. 36Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
8. 37Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our use of the tissue samples or other biological materials, which they provide to us, or otherwise arising from the collaboration
9. 38Third parties may assert that we are employing their proprietary technology without authorization
10. 39Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
11. 40Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights
12. 41We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
13. 42proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party’s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office
14. 43Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
15. 44Any patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO (or foreign patent offices)
16. 45Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
17. 46We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
18. 47Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
19. 48If we do not obtain patent term extension, data exclusivity and orphan exclusivity for any product candidates we may develop, our business may be materially harmed
20. 49If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
21. 50Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Our Reliance on Third Parties

1. 51If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms
2. 52We rely on third parties for tissue samples and other materials required for our research and development activities, and if we are unable to reach agreements with these third parties our research and development activities would be delayed
3. 53not be able to reach agreements with alternative partners or do so on terms acceptable to us. If we are unable to enter into such agreements, our research and development activities will be delayed and possibly impaired
4. 54If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected
5. 55Our suppliers and any future collaborators may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us

Risks Related to Managing Our Business and Operations

1. 56We may encounter difficulties in managing our growth, which could adversely affect our operations
2. 57If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive
3. 58Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
4. 59We use and generate materials that may expose us to material liability
5. 60If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
6. 61Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products
7. 62Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation

Risks Related to Our Common Stock

1. 63The price of our stock may be volatile, and you could lose all or part of your investment
2. 64We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
3. 65Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
4. 66If there are substantial sales of shares of our common stock, the price of our common stock could decline
5. 67Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
6. 68Our bylaws designate certain courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to litigate disputes with us in a different judicial forum
7. 69Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
8. 70Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
9. 71If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
10. 72We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
11. 73We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations
12. 74Changes in U.S. tax law could adversely affect our financial condition and results of operations
13. 75Our information systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
14. 76Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
15. 77Use of social media platforms presents risks and challenges
16. 78Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all